Drug Substitution

• 

  Subject Areas on Research

  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. 
  • ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. 
  • ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. 
  • Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. 
  • Application of antimicrobial stewardship to optimise management of community acquired pneumonia. 
  • Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. 
  • Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART. 
  • Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic. 
  • Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. 
  • Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). 
  • Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. 
  • Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. 
  • Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug. 
  • Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Direct oral anticoagulants: new drugs and new concepts. 
  • Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. 
  • Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. 
  • Effectiveness of antimicrobial guidelines for community-acquired pneumonia in children. 
  • Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. 
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. 
  • FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Generic clopidogrel: time to substitute? 
  • Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. 
  • Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. 
  • Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. 
  • Impact of restarting home neuropsychiatric medications on sedation outcomes in medical intensive care unit patients. 
  • In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. 
  • In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. 
  • Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. 
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. 
  • On the interchangeability of biologic drug products. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. 
  • Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. 
  • Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results. 
  • Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. 
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 
  • Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. 
  • Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. 
  • Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. 
  • Some thoughts on drug interchangeability. 
  • Statistical methods for assessing interchangeability of biosimilars. 
  • Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. 
  • Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. 
  • The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. 
  • Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. 
  • Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Using a Chord Diagram to Visualize Dynamics in Contraceptive Use: Bringing Data into Practice. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.